OABI
OmniAb, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.33
−8.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 38.4M | 18.7M | 26.4M | 34.2M | 59.1M |
| Cost of Revenue | 19.0M | 22.1M | — | — | — |
| Gross Profit | 19.4M | (3.4M) | 26.4M | 34.2M | 59.1M |
| Operating Expenses | |||||
| R&D Expense | 43.5M | 47.8M | 55.1M | 56.5M | 48.4M |
| SG&A Expense | 25.4M | 29.2M | 30.7M | 33.3M | 24.9M |
| General & Admin Expense | 20.1M | 29.2M | 30.7M | 33.3M | 24.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.1M) | (8.8M) | 15.0M | 13.7M | 12.5M |
| Total Operating Expenses | 67.8M | 68.1M | 100.9M | 103.6M | 85.7M |
| Cost and Expenses | 86.8M | 90.2M | 100.9M | 103.6M | 85.7M |
| Operating Income (EBIT) | (48.3M) | (71.5M) | (74.5M) | (69.4M) | (26.6M) |
| Non-Operating | |||||
| Interest Income | 2.3M | 2.7M | 3.1M | 5.1M | 587.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 2.3M | 2.7M | 3.1M | 5.1M | 587.0K |
| Other Non-Op Income/Expense | 4.5M | 5.2M | 3.1M | 5.1M | 587.0K |
| Non-Operating Income (excl Interest) | (4.5M) | (5.2M) | (3.1M) | (5.1M) | (587.0K) |
| EBT (Pre-Tax Income) | (43.8M) | (66.3M) | (71.4M) | (64.4M) | (26.1M) |
| Income Tax Expense | 441.0K | (1.5M) | (9.4M) | (13.7M) | (3.7M) |
| Bottom Line | |||||
| Net Income | (44.3M) | (64.8M) | (62.0M) | (50.6M) | (22.3M) |
| Earnings from Cont. Ops | (44.3M) | (64.8M) | (62.0M) | (50.6M) | (22.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (44.3M) | (64.8M) | (62.0M) | (50.6M) | (22.3M) |
| Per Share | |||||
| Basic EPS | ($0.36) | ($0.57) | ($0.61) | ($0.51) | ($0.26) |
| Diluted EPS | ($0.36) | ($0.57) | ($0.61) | ($0.51) | ($0.26) |
| Revenue Per Share | $0.30 | $0.16 | $0.26 | $0.34 | $0.69 |
| Shares | |||||
| Basic Shares Outstanding | 128.8M | 113.6M | 102.4M | 99.7M | 85.3M |
| Diluted Shares Outstanding | 128.8M | 113.6M | 102.4M | 99.7M | 85.3M |
| Profitability Metrics | |||||
| EBITDA | (25.5M) | (44.5M) | (47.8M) | (44.9M) | (7.8M) |
| D&A | 18.4M | 21.8M | 23.6M | 19.5M | 18.2M |
| EBIT | (43.8M) | (66.3M) | (71.4M) | (64.4M) | (26.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026